Breast cancer associated with intraductal papilloma
Yu. I. Gaman, 
V. I. Apanasevich,
A. V. Laguryova,
O. M. Zagrutdinova,
N. G. Plekhova,
O. A. Argishev,
V. I. Nevozhay,
Е. P. Kostiv
V. I. Apanasevich,
A. V. Laguryova,
O. M. Zagrutdinova,
N. G. Plekhova,
O. A. Argishev,
V. I. Nevozhay,
Е. P. Kostiv https://doi.org/10.17650/1994-4098-2023-19-3-25-29
Abstract
Background. Intraductal papilloma (IDP) is not usually considered as an obligate precancerous lesion since the cases of its progression into cancer are exceedingly rare.
Aim. To analyze the impact of IDP on the risk of breast cancer in the future.
Materials and methods. This retrospective study included patients aged 22–82 years operated on for IDP (n = 304) and other benign breast tumors (n = 304) between 2014 and 2022. We checked these patients in the cancer registry of Primorsky Regional Oncology Dispensary to find out whether any of them developed any type of cancer, including breast cancer. Then we calculated the odds of developing breast cancer in both groups.
Results and conclusion. We found that paients with a history of IDP are 2.4 times more likely to develop breast cancer. The incidence of other cancer types did not differ significantly between the two groups. Our findings are consistent with the results of similar foreign studies and might indicate that IDP and breast cancer share the same etiological factor. They can also highlight specific characteristics of asymptomatic IDP.
Supporting agencies: The study was performed without external funding
About the Authors
Yu. I. Gaman
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Yuliya Ivanovna Gaman
2a Prospekt Ostryakova, Vladivostok 690002
Competing Interests:
The authors declare no conflict of interest
V. I. Apanasevich
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
2a Prospekt Ostryakova, Vladivostok 690002
Competing Interests:
The authors declare no conflict of interest
A. V. Laguryova
Pacific State Medical University; Primorsky Regional Oncology Dispensary
Russian Federation
Competing Interests:
Russian Federation
2a Prospekt Ostryakova, Vladivostok 690002; 59 Russkaya St., Vladivostok 690105
Competing Interests:
The authors declare no conflict of interest
O. M. Zagrutdinova
Primorsky Regional Oncology Dispensary
Russian Federation
Competing Interests:
Russian Federation
59 Russkaya St., Vladivostok 690105
Competing Interests:
The authors declare no conflict of interest
N. G. Plekhova
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
2a Prospekt Ostryakova, Vladivostok 690002
Competing Interests:
The authors declare no conflict of interest
O. A. Argishev
Primorsky Regional Oncology Dispensary
Russian Federation
Competing Interests:
Russian Federation
59 Russkaya St., Vladivostok 690105
Competing Interests:
The authors declare no conflict of interest
V. I. Nevozhay
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
2a Prospekt Ostryakova, Vladivostok 690002
Competing Interests:
The authors declare no conflict of interest
Е. P. Kostiv
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
2a Prospekt Ostryakova, Vladivostok 690002
Competing Interests:
The authors declare no conflict of interest
References
1. Cancer Today International Agency for Research on Cancer/Cancer Today. Available at: https://gco.iarc.fr/today/online-analysis-pie.
2. The state of oncological care for the population of Russia in 2021. Ed. By A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: P. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia, 2022. Pp. 4, 5. (In Russ.)
3. Forman D., de Martel C., Lacey C.J. et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;5:12–23. DOI: 10.1016/j.vaccine.2012.07.055
4. Xiong W.M., Xu Q.P., Li X. et al. The association between human papillomavirusinfection and lung cancer: A system review and meta-analysis. Oncotarget 2017;8(56):9–32. DOI: 10.1016/j.vaccine.2012.07.055
5. Yang L., Xie S., Feng X. et al. Worldwide prevalence of human papillomavirus and relative risk of prostate cancer: a meta-analysis. Sci Rep 2015;5:46–67. DOI: 10.1038/srep14667
6. Volgareva G.M., Ermilova V.D. Detection of human papillomavirus type 18 oncogen e7 in patients with prostate cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2019;18(1):37–41. (In Russ.)
7. Zhang S.K., Guo L.W., Chen Q. et al. The association between human papillomavirus16 and esophageal cancer in Chinese population: a meta-analysis. BMC Cancer 2015;15:1–10. DOI: 10.1186/s12885-015-1096-1
8. Al-Shabanah O.A., Hafez M.M., Hassan Z.K. et al. Human papillomavirus genotyping and integration in ovariancancer Saudi patients. Virology J 2013;10:13–23. DOI: 10.1186/1743-422X-10-343
9. Li Y.X., Zhang L., Simayi D. et al. Human papillomavirus infection correlates with inflammatory Stat3-signaling activity and IL-17 level in patients with colorectal cancer. PLoS One 2015;10(2):11–9. DOI: 10.1371/journal.pone.0118391
10. Li N., Yang L., Zhang Y. et al. Human papillomavirus infection and bladder cancer risk: A meta-analysis. Infect Dis 2011;204(2): 217–23. DOI: 10.1093/infdis/jir248
11. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Available at: https://www.thelancet.com/journals/lanonc/article/PIIS1470204505700863/fulltext.
12. Guo H., Idrovo J.P., Cao J. et al. Human papillomavirus (HPV) detection by chromogenic in situ hybridization (CISH) and p16 immunohistochemistry (IHC) in breast intraductal papilloma and breast carcinoma. Clin Breast Cancer 2021;21(6):e638–e646. DOI: 10.1016/j.clbc.2021.04.006
13. Li N., Bi X., Zhang Y. et al. Human papillomavirus infection and sporadic breast carcinoma risk: A meta-analysis. Breast Cancer Treat 2011;126:515–20. DOI: 10.1007/s10549-010-1128-0
14. Simões P.W., Medeiros L.R., Simões Pires P.D. et al. Prevalence of human papillomavirus in breast cancer: A systematic review. Int Gynecol Cancer 2012;22:343–7. DOI: 10.1097/IGC.0b013e31823c712e
15. Sakai T., Makita M., Akiyama F. et al. Intraductal papilloma with bloody discharge from Montgomery’s areolar tubercle examined by ductoscopy from the areola. Breast Cancer 2006;13(1):104–6. DOI: 10.2325/jbcs.13.104
16. Li X., Wang H., Sun Z. et al. A retrospective observational study of intraductal breast papilloma and its coexisting lesions: A real-world experience. Cancer Med 2020;9(20):7751–62. DOI: 10.1002/cam4.3308
17. Ahmadiyeh N., Stoleru M.A., Raza S. et al. Management of intraductal papillomas of the breast: An analysis of 129 cases and their outcome. Ann Surg Oncol 2009;16(8):2264–9. DOI: 10.1245/s10434-009-0534-1
18. Balci F.L., Uras C., Feldman S.M. Is human papillomavirus associated with breast cancer or papilloma presenting with pathologic nipple discharge? Cancer Treat 2019;19:40–52. DOI: 10.1016/j.ctarc.2019.100122
19. Kudela E., Kudelova E., Kozubík E. et al. HPV-associated breast cancer: Myth or fact? Pathogens 2022;11(12):10–5. DOI: 10.3390/pathogens11121510
20. De Villiers E.M., Sandstrom R.E., zur Hausen H. et al. Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. Breast Cancer 2005;7:1–11. DOI: 10.1186/bcr940
Review
For citations:
Gaman Yu.I., Apanasevich V.I., Laguryova A.V., Zagrutdinova O.M., Plekhova N.G., Argishev O.A., Nevozhay V.I., Kostiv Е.P. Breast cancer associated with intraductal papilloma. Tumors of female reproductive system. 2023;19(3):25-29. (In Russ.) https://doi.org/10.17650/1994-4098-2023-19-3-25-29
Views:
514
Email this article 